AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

CHRS · NASDAQ · Biotechnology

Coherus Oncology

Commercializes LOQTORZI while advancing mid-stage immuno-oncology antibodies.

$1.39

After-hours close−0.02 (−1.42%)

At close$1.41(−3.42%)

Something off on this page? Send us feedback.

Profile

Coherus Oncology, Inc.CHRSHealth Care

Commercializes LOQTORZI for nasopharyngeal carcinoma and advances two mid-stage immuno-oncology antibodies. The business now centers on U.S. oncology sales, specialty-wholesale distribution, and clinical combinations after exiting its biosimilar franchises.

Commercializes LOQTORZI, a PD-1 inhibitor developed with Junshi Biosciences, for recurrent or metastatic nasopharyngeal carcinoma. Operations are primarily U.S.-based, with sales moving through specialty wholesalers and Puerto Rico included in distribution.

Advances casdozokitug, an IL-27 antagonist, and tagmokitug, an anti-CCR8 antibody, as mid-stage immuno-oncology candidates across liver, colorectal, head and neck, gastric, esophageal, and prostate cancer settings. The Surface Oncology acquisition brought these antibody programs into the current pipeline.

Carries a founder-led operating model after the UDENYCA sale and the exit from UDENYCA, YUSIMRY, and CIMERLI biosimilars. The business depends on LOQTORZI uptake, access through McKesson, Cencora, and Cardinal Health, clinical readouts, and funding the oncology pipeline after the biosimilar divestitures.

Company facts

CEODennis M. Lanfear

ListedNov 6, 2014

ExchangeNASDAQ

HeadquartersRedwood City, CA

CountryUnited States

Employees147

CIK0001512762

ISINUS19249H1032

Key statistics

Market cap$217.8M

EPS (ttm)−$1.02

P/E (ttm)−1.38

ROE-181.7%

P/B3.59

P/S4.28

Dividend yield—

Beta2.00vs XLV 0.15

Year to date +2.9% · Average volume (30d) 1.0M

Analysts

Price target, next 12 months$6.00+325.5%Median of 17 analysts · vs the Aug 28 close

ConsensusBuy14 of 17 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $1.41

High$11.00+680.1%

Median$6.00+325.5%

Low$1.05−25.5%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating
Sep 4, 2025	Maxim Group	Upgrade	Hold	Buy

Earnings

EPS

Estimate−$0.21

ReportedDue Nov 5, 2026

Revenue

Estimate$16.0M

ReportedDue Nov 5, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 5, 2026Q2 FY26	−$0.25	−$0.19	+24.0%	$14.4M	$14.3M	−0.7%	−13.10%
May 11, 2026Q1 FY26	−$0.26	−$0.25	+5.1%	$14.2M	$12.3M	−13.4%	−12.31%
Mar 9, 2026Q4 FY25	−$0.36	−$0.34	+4.2%	$13.9M	$12.7M	−8.4%	+1.04%
Nov 6, 2025Q3 FY25	−$0.32	−$0.33	−3.1%	$14.1M	$11.6M	−17.9%	−10.07%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$7.6M	$10.3M	$11.6M	$12.7M	$12.3M	$14.3M
Gross profit	$3.9M	$5.8M	$6.9M	$7.8M	$7.6M	$10.1M
Operating income	−$45.4M	−$45.5M	−$42.2M	−$45.9M	−$36.2M	−$32.3M
Net income	−$56.6M	−$41.3M	−$35.1M	−$37.3M	−$37.9M	−$20.6M
Diluted EPS	−$0.49	−$0.39	−$0.30	−$0.31	−$0.28	−$0.13
Gross margin	51.3%	57.0%	59.5%	61.2%	61.9%	70.4%
Operating margin	-597.9%	-443.6%	-365.0%	-359.9%	-293.7%	-226.0%

Fiscal years (4-quarter sums)FY21 $326.6M · FY22 $211.0M · FY23 $257.2M · FY24 $192.2M · FY25 $42.2M

Revenue by product · Q2 FY26

Product And Service, Other$694.0K · 100%

Balance sheet, Jun 30, 2026Cash & short-term investments $105.3M · Total debt $37.7M · Total assets $191.2M · Shareholders' equity $60.8M

Dividends

No dividends on record.

Ownership

Institutions 46.32%71.57M sharesInsiders 0.90%1.39M sharesOther 52.78%81.54M shares

Shares outstanding 154.50M · Float 134.81M · 87.3% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Timothy G. Youngquist 2020 Irrevocable Trust	13.05M	8.45%	13F	Aug 7, 2026
Rubric Capital Management LP	10.40M	9.03%	13G	Nov 13, 2024
BlackRock, Inc.	8.93M	5.80%	13G	Jul 27, 2026
Vanguard Capital Management LLC	5.95M	3.85%	13F	Aug 13, 2026
Geode Capital Management, LLC	3.69M	2.39%	13F	Aug 12, 2026

Insider tradesForm 4

No open-market trades in the last 12 months.